

**AMENDMENTS TO THE CLAIMS**

Please cancel claims ~~1-36~~ 1-27 without prejudice. Please add new claims ~~37-45~~ 28-36, as indicated below.

~~1-36~~ 1-27. (Canceled).

37 28. (Currently Amended) An oligonucleotide, comprising: 5'-TGACGTT-3', 5'TGACGTC3' or 5'-AACGTT-3', 8-40 nucleotides in length, and having at least one phosphate backbone modification.

38 29. (Currently Amended) The oligonucleotide of claim 37 28, wherein the oligonucleotide is linked to a nucleic acid delivery complex.

39 30. (Currently Amended) The oligonucleotide of claim 38 29, wherein the oligonucleotide is ionically linked to or encapsulated in the nucleic acid delivery complex.

40 31. (Currently Amended) The oligonucleotide of claim 38 29, wherein the oligonucleotide is covalently linked to the nucleic acid delivery complex.

41 32. (Currently Amended) The oligonucleotide of claim 38 29, wherein the nucleic acid delivery complex is a cationic lipid.

42 33. (Currently Amended) The oligonucleotide of claim 38 29, wherein the nucleic acid delivery complex is a sterol.

43 34. (Currently Amended) The oligonucleotide of claim 37 28, wherein the oligonucleotide comprises 5'-TCAACGTT-3'

44 35. (Currently Amended) The oligonucleotide of claim 42 33, wherein the phosphate backbone modification is a phosphorothioate.

45 36. (Currently Amended) A composition comprising the oligonucleotide of claim 37 28 and a pharmaceutically acceptable carrier.